Pursuant to the advice of the Chapter of the National Lipid Association, the following updates to the Bylaws are proposed to the NLA membership for adoption at the NLA Business Meeting on May 18, 2019. The purpose of the update is to restore the position of the at-large directors on the chapter boards of directors and eliminate the regional representative position. You may review the proposed changes by downloading the document at the link below.
Sanofi and Regeneron announced on Monday, Feb. 11 alirocumab will be made available at a reduced list price to help lower patient out-of-pocket costs and improve access.
Alan Brown, MD, FNLA
It has been an honor to serve as the President of the National Lipid Association (NLA) for the 2018-19 organizational year, and I look forward to the rest of my term through the 2019 Scientific Sessions. I hope everyone had a wonderful holiday and want to wish everyone a Happy New Year. I am excited for what 2019 has in store.